Gabapentin
Product Images NDC 50436-3011

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50436-3011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl504363011)

Label for gabapentin 600 mg tablets, containing 90 tablets. The label includes the product NDC 50436-3011, manufacturer's information for Unit Dose Services LLC located in Miami, FL, and storage instructions to keep the medication out of reach of children and store at controlled room temperature (20-25°C). The label also shows placeholders for lot number, expiration date, and manufacturer details with Sun Pharm.*

FDA Label Image

Spl-gabapentin-figure1 (Spl Gabapentin Figure1)

A line graph comparing weekly mean pain scores over 8 weeks for gabapentin 3,600 mg/day versus placebo. The x-axis shows weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis represents mean pain scores from 0 to 10. Gabapentin's mean pain score decreases steadily, while placebo remains relatively constant.*

FDA Label Image

Spl-gabapentin-figure2 (Spl Gabapentin Figure2)

Line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' depicting mean pain scores over 7 weeks. The x-axis shows Weeks (Baseline to 7), and the y-axis shows Mean Pain Score (0 to 10). Three lines represent Placebo, Gabapentin 1,800 mg/day, and Gabapentin 2,400 mg/day, showing score trends during a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Spl-gabapentin-figure3 (Spl Gabapentin Figure3)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' shows results from two studies. Study 1 compares placebo (12%) to gabapentin 3600 mg (29%). Study 2 compares placebo (14%) to gabapentin 1800 mg (32%) and 2400 mg (34%). Statistical significance levels (p<0.01 and p<0.001) are indicated for gabapentin groups versus placebo.*

FDA Label Image

Spl-gabapentin-figure4 (Spl Gabapentin Figure4)

A scatter plot showing responder rates in patients receiving gabapentin expressed as a difference from placebo. The x-axis represents daily dose in mg (600, 900, 1200, 1800), and the y-axis shows the percentage difference. Data points correspond to three different studies labeled as Study a, Study b, and Study c, with distinct markers. The graph illustrates dose-response relationships in adjunctive therapy for partial seizures in patients aged 12 years and older.*

FDA Label Image

Spl-gabapentin-formula (Spl Gabapentin Formula)

An illustration of the creatinine clearance (CLCr) formula, which calculates kidney function using age, weight, serum creatinine level, and an adjustment factor for female patients.*

FDA Label Image

Spl-gabapentin-structure (Spl Gabapentin Structure)

Chemical structure of gabapentin, showing a cyclohexane ring attached to a carbon bonded to an amino group (CH2NH2) and a carboxylic acid group (CH2CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.